Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Eleftherios Michailidis · EMORY UNIVERSITY · 2023 · $234,750 — Project Summary There are approximately a quarter of a billion people worldwide chronically infected with hepatitis B virus (HBV) who are at risk of developing liver cirrhosis and hepatocellular carcinoma. The loss of life due to HBV-related complications each year is about 820,000 people. At the sa…
Li Li · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $209,375 — ABSTRACT Gonorrhea affects over 87 million people annually globally. In 2019, over 600,000 cases of gonorrhea were reported to the CDC, a 92% increase since the historic low in the US in 2009. However, the true incidence of cases annually in the US is estimated to be ~1.5 million. The spread of anti…
Roger Sciammas · UNIVERSITY OF CALIFORNIA-IRVINE · 2023 · $776,774 — Project summary: The vast majority of mammalian genes produce alternatively processed mRNAs through alternative splicing and alternative polyadenylation (APA). Different mRNA isoforms produced from the same gene can encode distinct proteins and/or they may be differentially regulated. Recent studies…
John H Adams · UNIVERSITY OF SOUTH FLORIDA · 2023 · $975,499 — Project Summary/Abstract Plasmodium vivax is the second leading cause of malaria and the most prevalent cause of malaria outside of Africa. The estimated cost of the global burden of vivax malaria is $1.4 - $4 billion per year and more people live at risk worldwide from P. vivax than P. falciparum. …
Amit Kapoor · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2023 · $614,828 — Abstract Although direct acting antivirals can cure Hepatitis C virus (HCV) infection, a vaccine is necessary to stop new infections, and to prevent re-infections in the cured individuals. Studies in humans and chimpanzees suggest that both T cells and neutralizing antibodies (nAb) can play an impor…
Anna R. Smith · BOSTON UNIVERSITY MEDICAL CAMPUS · 2023 · $47,694 — ABSTRACT Alpha-1 antitrypsin deficiency (AATD) is a genetic disease most commonly caused by the Z point mutation in the SERPINA1 gene, resulting in misfolded Z-AAT protein polymerization in hepatocytes, cell death, and often cirrhosis. Replacement of ZZ with wild type MM hepatocytes via liver trans…
Scott M Husson · CLEMSON UNIVERSITY · 2023 · $179,097 — Project Summary Circular RNA (circRNA) has important, understudied roles all across physiology and disease. Additionally, circularization of protein-coding RNA is a promising strategy for increasing the duration and quantity of therapeutic protein production and decreasing immunogenicity relative to…
Frederic D Bushman · UNIVERSITY OF PENNSYLVANIA · 2023 · $1,529,954 — SUMMARY – mVACS PROGRAM Clostridioides difficile is the most reported nosocomial pathogen in the United States and a major public health threat worldwide. Challenges in treating infections with conventional antibiotics and increasing rates of recurrent infection underscore the need for new intervent…
Joseph Edgar Craft · YALE UNIVERSITY · 2023 · $648,096 — PROJECT SUMMARY A novel vaccine for Lyme disease Acquired resistance to Ixodes scapularis, commonly known as “tick resistance”, can prevent transmission of Borrelia burgdorferi, the Lyme disease agent. We have shown that tick resistance can be generated in guinea pigs (1) repeatedly exposed to I. s…
Ronald G Collman · UNIVERSITY OF PENNSYLVANIA · 2023 · $3,055,816 — CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the Universit…
Monica Gandhi · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $242,250 — PROJECT SUMMARY/ ABSTRACT At this point in the COVID-19 pandemic, with vaccine roll-out ongoing, one of the most urgent questions facing people living with HIV (PLWH) and their providers is whether HIV modulates the immune response to and subsequent effectiveness of the SARS-CoV-2 vaccines. Unfortu…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,829,883 — The development of an HIV vaccine has been hampered by unprecedented challenges, primarily due to the unique properties of the HIV-1 envelope (Env) trimer, a cleverly engineered entry machinery that features an extraordinary assortment of immune-evasion tactics, including antigenic variation, heavy …
Masaru Kanekiyo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $969,000 — Our previous work has led to the development of vaccines against respiratory syncytial virus and Zika that have reached late phase clinical testing. While we are still performing some exploratory studies on vaccine-elicited immunity following RSV vaccination, or work on emerging and resurgent viruse…
Edward M. Schwarz · UNIVERSITY OF ROCHESTER · 2022 · $274,504 — Abstract Osteomyelitis is the bane of orthopaedic surgery, of which the majority is caused by Staphylococcus aureus. Prior to this P50 Center of Research Translation on the Osteoimmunology of Bone Infection (CoRTOBI), it was known that these rare infections following elective surgery (~1%), and our …
RUTH R MONTGOMERY · YALE UNIVERSITY · 2022 · $802,136 — Abstract We propose single-cell technologies to quantify multiparameter immune markers that provide in- depth single-cell data for analysis of immune responses to vaccination in our study cohorts. The shared platforms in this service core provide efficient and reproducible profiling in support of ou…
JULIE AKE · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $17,792,120 — The NIAID Division of AIDS and the U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Development Command (MRDC) remain committed to the common objective of developing a safe and effective vaccine for HIV/AIDS. The Agencies recog…
Jared Paul May · UNIVERSITY OF MISSOURI KANSAS CITY · 2022 · $78,250 — This proposal will investigate the role severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N protein phase separation in disrupting cellular translation and RNA metabolism. N protein phase separation creates membraneless organelles and concentrates RNAs in a droplet (dense) phase. While N …
Vitaly V. Ganusov · UNIVERSITY OF TENNESSEE KNOXVILLE · 2022 · $591,637 — Research Summary Tuberculosis (TB), a disease caused by the bacteria Mycobacterium tuberculosis (Mtb), remains a major infec- tious disease of humans in the world. After the initial local infection of one site in the lung Mtb somehow dissem- inates in the lung and often spreads beyond the lung. In f…
Mehul Shamal Suthar · EMORY UNIVERSITY · 2022 · $756,174 — Humoral immunity is an essential component of the immune response to flavivirus infection. Primary infection generates a robust neutralizing antibody response that mediates viral control and protection. It is becoming increasingly apparent that secondary infection with a closely related flavivirus s…
Abha Sahni · UNIVERSITY OF TEXAS MED BR GALVESTON · 2022 · $197,500 — PROJECT SUMMARY Precise and dynamic alterations in gene expression are critical determinants of the regulation of host immunity to microbial pathogens. Pathogenic rickettsiae in the spotted fever group cause some of the most severe infectious diseases in humans, characterized by microvascular inflam…